- About Us
- Our Research
- Diseases and conditions
- Research Departments
- Research support and facilities
- Aboriginal and Torres Strait Islander Health
- Participate in our research
- Research history
- Glossary of research terms
- Support Us
- Why support QIMR Berghofer?
- Ways to help
- Donate Now
- Join the Rio Tinto Ride to Conquer Cancer
- Buy Christmas cards and hampers
- Join our Regular Giving Club
- Join the Weekend to End Women's Cancers
- Leave a bequest in your will
- Corporate partnerships
- Workplace giving
- Fundraise for QIMR
- Attend a fundraising event
- Tribute gifts
- In memoriam gifts
- Stories of hope
- Book a tour or guest speaker
- Our supporters
- Thanks to our donors
- News & Events
- Contact Us
- Our Services
- CMV study
- Queensland Pancreatic Cancer Study
- QIMR Berghofer Centre for Immunotherapy and Vaccine Development
|Share on Facebook||Share on Twitter||Share on LinkedIn|
Associate Professor David Harrich, from QIMR’s Molecular Virology Laboratory, has determined how to modify a protein in the virus, so that it instead provides strong, lasting protection from infection.
“This is like fighting fire with fire, Associate Professor Harrich said.
“If this research continues down its strong path, and bear in mind there are a many hurdles to clear, we’re looking at a cure for AIDS.
Associate Professor Harrich runs the only research laboratory and containment facilities in Queensland working with the HIV virus.
He invented the “Nullbasic protein by mutating an existing HIV protein. It’s shown remarkable abilities to stop the virus replicating in a lab environment. Animal trials are due to start this year.
“I have never seen anything like it. The modified protein works every time, Assoc Prof Harrich said.
“You would still be infected with HIV, it’s not a cure for the virus. But the virus would stay latent, it wouldn’t wake up, so it wouldn’t develop into AIDS. With a treatment like this, you would maintain a healthy immune system.
The successful development of this type of one-off treatment would also have economic implications. HIV patients currently take a regime of drugs for the rest of their lives, which can be a significant financial burden.
Associate Professor Harrich has been researching HIV for thirty years, since starting as a research assistant at the University of California, Los Angeles (UCLA) in the early 1980s when the first cases of HIV/AIDS emerged.
“I’ve come close to giving up in the past. But today I’m so encouraged. I feel very fortunate because not a lot of scientists are able to stay in the same game long enough to see these sorts of developments. It involves perseverance, dedication and, of course, sustained research funding.
Associate Professor Harrich’s research is funded by an Australian Research Council Future Fellowship.